Answers are grounded in this paper and cite their sources.
Background Gabapentinoids, namely pregabalin and gabapentin, are increasingly prescribed for neurological, pain-related, and psychiatric conditions. Although initially considered to have low misuse potential, accumulating evidence has linked these medications to misuse, dependence, diversion, and overdose, particularly among individuals with substance use disorders. Evidence from Western countries has expanded, but findings from the Arab world remain fragmented. This narrative review examines patterns of gabapentinoid misuse in the Arab world, including user characteristics, risk factors, community pharmacists’ perspectives, and regulatory responses. Main body Studies from Egypt, Jordan, Saudi Arabia, the United Arab Emirates, Oman, Lebanon, and Sudan document gabapentinoid misuse as a regional public health concern in selected populations. Misuse is most frequently reported among males, individuals with substance use disorders, particularly opioid use disorder, and those with psychiatric comorbidities. Common motivations for gabapentinoid use include self-medication for anxiety, sleep disturbances, and pain; recreational use; and enhancement of the effects of other psychoactive substances. Non-prescription access through community pharmacies, extensive off-label prescribing, and limited surveillance systems are recurring themes. Community pharmacists frequently report suspected misuse and emphasize the need for stronger regulatory oversight, professional training, and monitoring. Although regulatory restrictions have been associated with reduced pregabalin utilization and changes in the use of other medications, individual-level substitution remains unestablished. The predominantly cross-sectional evidence also precludes reliable estimates of regional prevalence and trends over time. Conclusion Gabapentinoid misuse represents an important but insufficiently characterized public health concern in the Arab world. Addressing existing evidence gaps requires strengthening gabapentinoid monitoring within national electronic prescribing systems, adopting a common minimum regional surveillance dataset, implementing brief pharmacy screening and referral procedures, and expanding regional research, while maintaining access to appropriate treatment.
No takes yet. Share an insight, caveat, or question.
Khalifeh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: